Detalhe da pesquisa
1.
Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Clin Infect Dis
; 76(6): 996-1002, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36345569
2.
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.
Clin Infect Dis
; 76(3): 389-397, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36189636
3.
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.
New Microbiol
; 42(2): 101-107, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31034084
4.
The maraviroc expanded access program - safety and efficacy data from an open-label study.
HIV Clin Trials
; 16(1): 10-21, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25777185
5.
An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index.
BMC Public Health
; 14: 80, 2014 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24461042
6.
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Nat Med
; 11(11): 1170-2, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16205738
7.
Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med
; 359(14): 1429-41, 2008 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-18832244
8.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
N Engl J Med
; 359(14): 1442-55, 2008 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-18832245
9.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
J Infect Dis
; 201(6): 803-13, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20151839
10.
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Lancet HIV
; 8(2): e77-e86, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539761
11.
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.
HIV Clin Trials
; 11(3): 145-55, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736151
12.
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Br J Clin Pharmacol
; 65 Suppl 1: 86-94, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18333870
13.
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Br J Clin Pharmacol
; 65 Suppl 1: 5-18, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18333861
14.
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
PLoS One
; 13(12): e0204099, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586365
15.
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Pediatr Infect Dis J
; 37(5): 459-465, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023357
16.
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Clin Pharmacol Ther
; 78(5): 508-19, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16321617
17.
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
Antivir Chem Chemother
; 16(6): 339-54, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16329283
18.
Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
Ann N Y Acad Sci
; 1346(1): 7-17, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25962411
19.
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Antivir Chem Chemother
; 27: 2040206619895706, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856576
20.
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
AIDS
; 28(5): 717-25, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24983542